Keyphrases
Biosimilar
100%
Moderate-to-severe Psoriasis
100%
Drug Survival
100%
Safety Efficacy
100%
Ustekinumab
50%
Infliximab
37%
Etanercept
37%
Adalimumab
37%
Adverse Events
25%
Psoriasis
12%
Enbrel
12%
Severity Index
12%
Time to Discontinuation
12%
Long-term Safety
12%
Cox Regression
12%
Real-life Data
12%
Survival Trends
12%
Psoriasis Severity
12%
Biological Agents
12%
No Significant Difference
12%
Safety Profile
12%
Curve Regression
12%
Area Index
12%
Nave
12%
Kaplan-Meier Survival Curves
12%
Remicade
12%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
100%
Biosimilar Agent
100%
Secukinumab
100%
Psoriasis Vulgaris
100%
Etanercept
62%
Infliximab
62%
Ustekinumab
50%
Psoriasis
37%
Adalimumab
37%
Adverse Event
25%
Infection
12%
Overall Survival
12%
Immunology and Microbiology
Secukinumab
100%
Biological Product
100%
Infliximab
62%
Etanercept
62%
Ustekinumab
50%
Adalimumab
37%
Overall Survival
12%